Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality DOI Open Access
Stefano Ballestri, Alessandro Mantovani, Maria Di Girolamo

et al.

Metabolism and Target Organ Damage, Journal Year: 2023, Volume and Issue: 3(1), P. 1 - 1

Published: Jan. 1, 2023

Liver fibrosis is critical for liver-related outcomes and mortality in chronic liver disease, irrespective of etiology, including nonalcoholic fatty disease (NAFLD). NAFLD has been viewed as an independent correlate cardiovascular risk. This review article briefly describes the cellular molecular pathomechanisms underlying hepatic fibrosis. We then address noninvasive assessment Finally, we discuss published evidence supporting biomarkers’ role assessing risk among patients with NAFLD. While histological diagnostic standard fibrosis, specifically techniques, equations based on anthropometric parameters, laboratory indices, elastometry obtained imaging techniques. The former group includes AST: ALT ratio, Forns Index, AST-to-platelet ratio index score, BARD (BMI, AAR, Diabetes) fibrosis-4 (FIB-4), gamma-glutamyl transferase-to-platelet Hepamet score. latter comprises elastographic techniques associated ultrasonography or magnetic resonance. Our literature identified numerous studies demonstrating that biomarkers (the most common being FIB-4) predict overall major events patients. mechanisms accounting this association are reviewed. In addition to at baseline, during follow-up, after therapeutic interventions patients, may these

Language: Английский

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) DOI Creative Commons
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(3), P. 492 - 542

Published: June 7, 2024

Language: Английский

Citations

314
Changing epidemiology, global trends and implications for outcomes of NAFLD DOI Creative Commons
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 842 - 852

Published: May 10, 2023

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common globally, currently estimated to affect 38% of global population. A minority patients with NAFLD will progress cirrhosis or hepatocellular carcinoma, but total number this vast population that risk such severe outcomes is increasing. Worryingly, persons are affected by at an earlier age, suggesting they have longer time develop complications. With considerable changes in diet composition and urbanization, obesity type 2 diabetes among population, particular developing countries, proportion projected be further Yet, there large geographical discrepancies prevalence rates its inflammatory component non-alcoholic steatohepatitis (NASH). Such differences partly related differing socio-economic milieus, also genetic predisposition.This narrative review discusses recent epidemiology NASH from regional perspectives, as well special populations. We discuss consequences these can on hepatic extra-hepatic events.

Language: Английский

Citations

287
Lifestyle interventions in nonalcoholic fatty liver disease DOI
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(11), P. 708 - 722

Published: July 4, 2023

Language: Английский

Citations

136
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study DOI Creative Commons
Daniel Q. Huang, Laura Wilson, Cynthia Behling

et al.

Gastroenterology, Journal Year: 2023, Volume and Issue: 165(2), P. 463 - 472.e5

Published: April 29, 2023

Language: Английский

Citations

86
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis DOI
Monica A. Tincopa, Rohit Loomba

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2023, Volume and Issue: 8(7), P. 660 - 670

Published: April 13, 2023

Language: Английский

Citations

84
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold DOI Open Access
Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 46(7), P. 1354 - 1362

Published: April 12, 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter, prospective study assessed the yield of using routinely available data to identify these patients. RESEARCH DESIGN AND METHODS A total 713 outpatients T2DM, screened four diabetology clinics fatty liver disease according American Diabetes Association criteria, were referred hepatologists further work-up (Fibrosis-4 vibration-controlled transient elastography [VCTE]). biopsy was proposed when ALT levels persistently >20 IU/L female patients >30 male patients, absence other disease. RESULTS Liver biopsies performed 360 considered adequate reading after central review 330 specimens (median patient age, 59 years; 63%; median BMI HbA1c values, 32 7.5%, respectively). Prevalence NASH, AF, cirrhosis 58%, 38%, 10%, respectively. lesions independently associated components metabolic syndrome but not micro- macrovascular complications T2DM. Models based on without VCTE had good accuracy predict AF (respectively: area under receiver operating characteristic curve [AUROC], 0.84 0.77; correctly classified 59% 45%) NASH AUROC, 0.82 0.81; 44% 42%). CONCLUSIONS Despite use a low threshold, prevalence (58%) (38%) high. Routinely high identifying T2DM and/or requiring assessment.

Language: Английский

Citations

74
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD DOI Creative Commons
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(6), P. 1482 - 1490

Published: Aug. 13, 2022

Language: Английский

Citations

72
Noninvasive Assessment of Liver Fibrosis in NAFLD DOI Creative Commons
Arun J. Sanyal, Laurent Castéra, Vincent Wai‐Sun Wong

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 21(8), P. 2026 - 2039

Published: April 14, 2023

Language: Английский

Citations

71
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis DOI Creative Commons
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2023, Volume and Issue: 8(9), P. 829 - 836

Published: July 4, 2023

Summary

Background

Data are scarce regarding the development of hepatic decompensation in patients with non-alcoholic fatty liver disease (NAFLD) and without type 2 diabetes. We aimed to assess risk people NAFLD

Methods

did a meta-analysis individual participant-level data from six cohorts USA, Japan, Turkey. Included participants had magnetic resonance elastography between Feb 27, 2007, June 4, 2021. Eligible studies included those fibrosis characterisation by elastography, longitudinal assessment for death, adult (aged ≥18 years) NAFLD, whom were available presence diabetes at baseline. The primary outcome was decompensation, defined as ascites, encephalopathy, or variceal bleeding. secondary hepatocellular carcinoma. used competing regression using Fine Gray subdistribution hazard ratio (sHR) compare likelihood Death event.

Findings

2016 (736 diabetes; 1280 diabetes) this analysis. 1074 (53%) female mean age 57·8 years (SD 14·2) BMI 31·3 kg/m2 7·4). Among 1737 (602 1135 data, 105 developed over median follow-up time 2·8 (IQR 1·4–5·5). Participants significantly higher 1 year (3·37% [95% CI 2·10–5·11] vs 1·07% [0·57–1·86]), 3 (7·49% [5·36–10·08] 2·92% [1·92–4·25]), 5 (13·85% [10·43–17·75] 3·95% [2·67–5·60]) than (p<0·0001). After adjustment multiple confounders (age, BMI, race), (sHR 2·15 1·39–3·34]; p=0·0006) glycated haemoglobin (1·31 1·10–1·55]; p=0·0019) independent predictors decompensation. association remained consistent after baseline stiffness determined elastography. Over 2·9 1·4–5·7), 22 1802 analysed (18 639 four 1163 incident carcinoma (1·34% 0·64–2·54] 0·09% [0·01–0·50], (2·44% [1·36–4·05] 0·21% [0·04–0·73]), (3·68% [2·18–5·77] 0·44% [0·11–1·33]) Type an predictor 5·34 [1·67–17·09]; p=0·0048).

Interpretation

is associated

Funding

National Institute Diabetes Digestive Kidney Diseases.

Language: Английский

Citations

71
A global research priority agenda to advance public health responses to fatty liver disease DOI Creative Commons
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 618 - 634

Published: June 20, 2023

An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications this are profound. This study aimed develop an aligned, prioritised research agenda for global community.

Language: Английский

Citations

69